Acrivon therapeutics to present at the oppenheimer 33rd annual healthcare conference

Watertown, mass., march 06, 2023 (globe newswire) -- acrivon therapeutics, inc. (“acrivon” or “acrivon therapeutics”) (nasdaq: acrv), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, today announced the company's chief executive officer and president, peter blume-jensen, m.d., ph.d., will present a company overview on monday, march 13, 2023 at 3:20 p.m. et at the oppenheimer 33rd annual healthcare conference taking place virtually.
ACRV Ratings Summary
ACRV Quant Ranking